As of 2025-07-08, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is -50.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 2,599.63 mil USD. SRPT's TTM EBITDA according to its financial statements is -51.77 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 13.0x | 11.6x |
| Forward P/E multiples | 11.6x - 31.7x | 16.0x |
| Fair Price | (14.70) - 129.38 | 22.84 |
| Upside | -184.9% - 647.0% | 31.9% |
| Date | EV/EBITDA |
| 2025-07-03 | -51.96 |
| 2025-07-02 | -51.87 |
| 2025-07-01 | -50.95 |
| 2025-06-30 | -49.80 |
| 2025-06-27 | -49.81 |
| 2025-06-26 | -50.04 |
| 2025-06-25 | -50.48 |
| 2025-06-24 | -53.36 |
| 2025-06-23 | -53.16 |
| 2025-06-20 | -55.45 |
| 2025-06-18 | -56.76 |
| 2025-06-17 | -58.26 |
| 2025-06-16 | -57.09 |
| 2025-06-13 | -86.02 |
| 2025-06-12 | -88.16 |
| 2025-06-11 | -89.11 |
| 2025-06-10 | -91.50 |
| 2025-06-09 | -92.72 |
| 2025-06-06 | -98.98 |
| 2025-06-05 | -91.77 |
| 2025-06-04 | -92.39 |
| 2025-06-03 | -91.12 |
| 2025-06-02 | -88.98 |
| 2025-05-30 | -88.71 |
| 2025-05-29 | -90.63 |
| 2025-05-28 | -88.01 |
| 2025-05-27 | -90.13 |
| 2025-05-23 | -89.28 |
| 2025-05-22 | -90.97 |
| 2025-05-21 | -93.36 |
| 2025-05-20 | -93.25 |
| 2025-05-19 | -89.36 |
| 2025-05-16 | -86.49 |
| 2025-05-15 | -84.29 |
| 2025-05-14 | -85.18 |
| 2025-05-13 | -86.05 |
| 2025-05-12 | -86.38 |
| 2025-05-09 | -86.19 |
| 2025-05-08 | -86.66 |
| 2025-05-07 | -87.04 |
| 2025-05-06 | -106.08 |
| 2025-05-05 | -138.18 |
| 2025-05-02 | -137.90 |
| 2025-05-01 | -136.51 |
| 2025-04-30 | -135.79 |
| 2025-04-29 | -132.85 |
| 2025-04-28 | -134.10 |
| 2025-04-25 | -132.07 |
| 2025-04-24 | -134.57 |
| 2025-04-23 | -130.27 |